NRIX | Ticker Profile - Titan Protect

NRIX

Nurix Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$14.64

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.10

Based on estimated future earnings — lower means cheaper

Rev Growth

-66.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-61.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+105% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 17 analysts covering this stock

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

https://www.nurixtx.com

Country: United States Employees: 317 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.439

Positive but modest risk-adjusted returns

Kelly Fraction

0.0291

Modest edge detected — smaller position warranted

Calmar Ratio

0.116

Drawdown risk outweighs the returns — higher risk profile

Annual Return

8.2%

Historical annualised return based on price data

Max Drawdown

-70.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.88

Significantly more volatile than the market

52W High

$22.50

35% below the year high

52W Low

$8.20

79% above the year low

Avg Volume

1,133,447

Average daily shares traded — higher means easier to buy and sell

Short Ratio

21.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

18.2%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.20

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.01

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.89

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,479.4%

Profit from core operations before interest and tax

Free Cash Flow

$-145,462,624

Negative — the business is spending more than it generates

Revenue (TTM)

$72M

Total revenue over the last 12 months

Net Income

$-295,280,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$41.00

Target Median

$30.00

Target Low

$23.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go